The weight-loss drug Wegovy may lower the risk of heart attack , stroke or death more than similar medications, according to new research from its maker, Novo Nordisk . In a study of more than 21,000 patients with obesity and heart disease but no diabetes, those taking Wegovy -- which contains the active ingredient semaglutide -- saw a 57% greater reduction in heart-related risks compared to people taking tirzepatide, the ingredient in Eli Lilly 's weight-loss drugs Mounjaro and Zepbound . The